# US 2017/0281808 A1 · Monoclonal antibody and a method thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281808 A1
- Document ID: US20170281808A1
- Status: Published application
- Kind: A1
- Application number: 15/609,625
- Filed: 2017-05-31
- Published: 2017-10-05
- Earliest claimed: 2008-03-14
- Assignees: Biocon Limited; Centro De Inmunologia Molecular
- Applicants: Biocon Limited; Centro De Inmunologia Molecular
- Inventors: RAMAKRISHNAN MELARKODE; PRADIP NAIR; SUNDARAJ DAVID RAJKUMAR; KEDARNATH NANJUND SASTRY; MONALISA CHATTERJI; LAXMI ADHIKARY; HEMA BALASUBRAMANIAN; MONTERO CASIMIRO; JOSEFA LOMBARDERO VALLADARES; ROLANDO PEREZ RODRIGUEZ
- Web page: https://patentgrep.com/patent/US20170281808A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.

## Claims

### Claim 1

A method of inhibiting naïve T cell proliferation, the method comprising administering a therapeutically effective amount of a monoclonal anti-CD6 antibody that binds to domain 1(D1) of CD6 without interfering with ALCAM binding, wherein the monoclonal antibody comprises heavy and light chain variable regions comprising amino acid sequences as set forth in SEQ ID NOs: 1 and 2.

### Claim 2 (depends on 1)

The method of claim 1, wherein the monoclonal anti-CD6 further down regulates proinflammatory cytokines IL6 and INFγ.

### Claim 3

A method of treatment for an inflammatory disorder, the method comprising administering to a patient a therapeutically effective amount of a monoclonal anti-CD6 antibody that binds to domain 1 (D1) of CD6 without interfering with ALCAM binding, wherein the monoclonal antibody comprises heavy and light chain variable regions comprising amino acid sequences as set forth in SEQ ID NOs: 1 and 2, wherein the inflammatory disorder is type 1 diabetes

### Claim 4 (depends on 3)

The method of claim 3, wherein the therapeutically effective amount is a dose of 0.1 to 25 mg/Kg/week.

### Claim 5 (depends on 3)

The method of claim 3, wherein the monoclonal anti-CD6 antibody is administered in combination with antigens capable of eliciting an anti-inflammatory immune response selected from a group comprising Glutamic acid decarboxylase (GAD), Heat Shock Protein 60 (HSP60), and insulin.

### Claim 6 (depends on 3)

The method of claim 3, wherein SEQ ID NOs: 1 and 2 are encoded by SEQ ID NOs: 3 and 4 respectively.
